Penpulimab plus anlotinib as first-line treatment for persistent, recurrent, or metastatic cervical cancer: A multicentre, single-arm, phase II trial.
| Published in: | Journal of Clinical Oncology Vol. 44; pp. 211 - 234 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Published: |
American Society of Clinical Oncology
2026 Supplement 19
|
| Online Access: | View this record in EBSCOhost |